Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Baxter
McKinsey
Abbott
Colorcon

Last Updated: October 16, 2019

DrugPatentWatch Database Preview

Ireland Supplementary Protection Certificates

See Plans and Pricing

« Back to Dashboard

Supplementary Protection Certificates in Ireland

These international patent data are derived from patent families, based on US drug-patent linkages. Accordingly, they should not be regarded as comprehensive records of ex-US drug-patent associations.
Country Patent Number Supplementary Protection Certificate SPC Country SPC Description SPC Expiration
European Patent Office 1781688 2016/013 Ireland PRODUCT NAME: CARFILZOMIB OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTRATION NO/DATE: EU/1/15/1060 20151119   Request a Trial
European Patent Office 2145629 2013/025 Ireland PRODUCT NAME: BOTULINUM TOXIN TYPE A; NAT REGISTRATION NO/DATE: PA0148/060/001 20130117; FIRST REGISTRATION NO/DATE: PA018/060/002 17/01/2013 IRELAND PA0148/060/003 17/01/2013 FINLAND 25162 16/01/2013 FINLAND 15424 16/01/2013 FINLAND 28146 20130116   Request a Trial
European Patent Office 2487163 2016/062 Ireland PRODUCT NAME: COBICISTAT OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND ATAZANAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR ATAZANAVIR SULFATE; REGISTRATION NO/DATE: EU/1/15/1025 20160713   Request a Trial
European Patent Office 1203761 2005/020 Ireland PRODUCT NAME: CINACALCET OR A PHARMACEUTICALLY ACCEPTABLE SALT OR COMPLEX THEREOF, ESPECIALLY CINCALCET HYDROCHLORIDE; NAT REGISTRATION NO/DATE: EU/1/04/292/001-012 20041022; FIRST REGISTRATION NO/DATE: EU/1/04/293/001-012 20041022   Request a Trial
European Patent Office 2487166 2016/061 Ireland PRODUCT NAME: COBICISTAT OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND TENOFOVIR ALAFENAMIDE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR TENOFOVIR ALAFENAMIDE FUMARATE; REGISTRATION NO/DATE: EU/1/15/1061 20151119   Request a Trial
European Patent Office 1409016 2010/034 Ireland PRODUCT NAME: DENOSUMAB (PROLIA ); NAT REGISTRATION NO/DATE: EU/1/10/618/001 20100526; FIRST REGISTRATION NO/DATE: EU/1/10/618/002 26/05/2010 IRELAND EU/1/10/618/003 26/05/2010 IRELAND EU/1/10/618/004 26/05/2010 IRELAND EU/1/10/618/001 26/05/2010 IRELAND EU/1/10/618/002 26/05/2010 IRELAND EU/1/10/618/003 26/05/2010 IRELAND EU/1/10/618/004 20100526   Request a Trial
European Patent Office 1267866 2013/014 Ireland PRODUCT NAME: GLYCOPYRRONIUM OR A SALT THEREOF; REGISTRATION NO/DATE: EU/1/12/788/001-006 20120928   Request a Trial
>Country >Patent Number >Supplementary Protection Certificate >SPC Country >SPC Description >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Baxter
Medtronic
Dow
Abbott

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.